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cases revealed three novelmutations in the TPM1 gene; IVS1+2T N C, I130V, S229F and a polyadenylation signal
site variant GATAAA/AATAAA. Analysis of IVS1+2T N C revealed aberrant pre-mRNA splicing. In addition, abnor-
mal structural properties were found in hearts transfectedwith TPM1 carrying I130V and S229F mutations. Phe-
notypic analysis of TPM1morpholino-treated embryos revealed roles for TPM1 in cardiac looping, atrial septation
and ventricular trabeculae formation and increased apoptosis was seen within the heart. In addition, sarcomere
assembly was affected and altered action potentials were exhibited. This study demonstrated that sarcomeric
TPM1 plays vital roles in cardiogenesis and is a suitable candidate gene for screening individuals with isolated
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The heart is ﬁrst seen as a tube early in development, which un-
dergoes a series of complex processes to form a four-chambered struc-
ture. Looping of the chicken primitive heart tube is initiated from
Hamburger and Hamilton (HH) 10 (human gestation day 22) [1,2].
This tube subsequently divides into chambers by septation, initiated in
the primitive single atrium from the dorso-cranial wall around HH14
(4th week in human) followed by septation of the common ventricle
[3]. In humans, congenital heart defects (CHDs) occur in approximately
1 in 145 live births [4]. Althoughmost cases of CHDs are thought to have
complex etiology, some cases segregate through families following
Mendelian patterns of inheritance. Studying the genetic causes of the
Mendelian variety could potentially unravel the biology of this disease,
which, in turn, could be applied to the prevention and treatment ofngham, Queens
access article undercomplex-etiology CHD. The molecular genetics of Mendelian CHDs are
being elucidated, withmutations found in several genes, including tran-
scription factors NKX2 homeobox 5 (NKX2.5) and T-box 5 (TBX5), and
structural proteinsmyosin heavy chain 6 (MYH6), MYH7 and alpha car-
diac actin [5–7].
The cardiac conduction system (CCS) also appears early in
cardiogenesis with the development of a primordial pacemaker, and
subsequent formation continues with differentiation of the Purkinje ﬁ-
bres still ongoing around birth. The CCS is also susceptible to defects
with associated mutations in several genes; malformations may occur
in isolation or in association with structural defects such as atrial septal
defects (ASDs) [8]. Although much progress has been made in the un-
derstanding of cardiogenesis and its contribution to CHDs and CCS
malformations, the causative genetic determinants remain unknown
in most cases.
Cardiomyopathies are contractile diseases of the heart, which are as-
sociated with heart enlargement and dysfunction. The most common
types are hypertrophic and dilated cardiomyopathy (HCM andDCM, re-
spectively). HCM is deﬁned as a notable thickening of the ventricularthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tion [9]. Mutations in a range of sarcomeric genes have been associated
with both HCM and DCM, including Tropomyosin 1 (TPM1) [10,11]. Fur-
ther, a number of genes encoding structural proteins have been associ-
ated with both cardiomyopathies and CHDs in the same individuals,
such as TPM1,MYH7 and alpha cardiac actin [6,12–14]. Fewer sarcomeric
genes, such asMYH6 and alpha cardiac actin, have been associated with
isolated CHDs [5,7,15], or with the developing heart [16].
Tropomyosin regulates contraction of the sarcomere, through direct
interaction with actin and troponin T [17]. In the presence of elevated
levels of intracellular calcium (Ca2+), Ca2+ binds to troponin C of the
troponin complex inducing conformational changes that moves tropo-
myosin across the actin ﬁlament, exposing the myosin-binding sites,
allowing the globular myosin heads to interact. This produces move-
ment of the thick and thin ﬁlaments relative to each other, resulting in
sarcomere shortening and hence muscle contraction [18,19]. Despite
this essential interaction, roles for TPM1 in the developing heart are
poorly understood, with isolated CHD causative mutations previously
not described within the literature. Because of the aforementioned in-
volvement of other genes encoding components of the thick and thinﬁl-
aments of the cardiac sarcomere in both cardiomyopathy and heart
development, we aimed to screen TPM1 in a cohort of patients with di-
agnosed CHDs (presented in this report). Our initial results prompted us
to investigate developmental roles of TPM1 and its associated thin ﬁla-
ment protein cardiac Troponin T (cTNT) [16].
Here we report the screening of the TPM1 gene in 380 patients
with various CHDs. Four variants were detected. A splice donor sitemu-
tation resulted in abnormal splicing of pre-mRNA, while two non-
synonymous mutations failed to incorporate with the sarcomeric
protein cardiac troponin T in the sarcomere. Additionally, we detected
a polyadenylation site variant. We showed that upon treatment with
TPM1-speciﬁc morpholino oligonucleotides, the atrial septum and ven-
tricular trabeculae developed abnormally. Additionally, some hearts
showed abnormal looping. Although mature sarcomeres formed nor-
mally, there were fewer mature structures and increased apoptosis in
the TPM1 morpholino-treated hearts. Further, the action potential
(AP) of the cardiomyocytes was affected. These data suggest that
TPM1 is essential for normal heart development and contractile func-
tion. Screening detected four variants in the TPM1 gene, of which
three we predict would lead to a pathological phenotype; we therefore
consider TPM1 a gene worthy of screening patients afﬂicted with CHDs
or conduction anomalies.
2. Materials and methods
2.1. Phenotyping of patients
Patients with any form of CHD were recruited. All volunteered to
participate and were under the routine care of the East Midlands Con-
genital Heart Centre, Leicester, UK. All patients had their CHD diagnosed
fully by echocardiography and any other diagnostic modalities needed.
All phenotyping, non-cardiac diagnoses and family histories were con-
ﬁrmed by one of the authors (Bu'Lock) who is an experienced Consul-
tant Congenital and Paediatric Cardiologist.
2.2. Mutational dHPLC analysis
dHPLC analysis was completed as previously described [20] under
consent from participants and according to local ethics committees.
Samples of peripheral blood were collected from all participants. Geno-
mic DNAwas puriﬁed from the blood samples using QIAmp DNA blood
Midi Kit (Qiagen). Control DNA from anonymous human UK blood do-
nors was obtained from the European Collection of Cell Culture
(Salisbury). The mutational analysis by dHPLC was performed by de-
signing 14 PCR assays to cover the exons of the TPM1 gene and their sur-
rounding sequences (see Table S1). The melting temperature (Tm) foreach amplicon was calculated with the following formula: Tm =
63.728 + (0.41 × %GC) – (600/length) where %GC = percentage GC
of the primer; length= length of the primer in nucleotides. The anneal-
ing temperature used was the average of the two primer Tms + 3 °C.
PCR products were obtained by standard protocols from patient ge-
nomic DNA. After ampliﬁcation, a ﬁnal hybridization step was carried
out, starting at 95 °C and reducing the temperature by 1.5 °C perminute
to 25 °C in order to favour the formation of heteroduplexes. The se-
quence of each amplicon was analysed using the Navigator software
(Transgenomic) to determine themelting proﬁle of each DNA fragment
and select the optimal temperatures for dHPLC. PCR products were
processed using the dHPLC WAVE System (Transgenomic). PCR prod-
ucts from samples showing a dHPLC trace suggestive of variation were
ampliﬁed again and sequenced using standard protocols. Potentially
deleterious variants were screened by dHPLC in 380 individuals with a
CHD and 384 ethnically matched control subjects.
2.3. Homology molecular model of the S229F TPM1 protein
The molecular model of the S229F TPM1 mutant protein was made
by comparing human wild-type TPM1 protein with the known struc-
ture of other tropomyosin proteins [21] (Protein Data Bank ID:1C1G).
Images were prepared using PyMOL Molecular Graphics System soft-
ware v0.99 (DeLano Scientiﬁc).
2.4. Splicing-donor site mutation of TPM1
Genomic DNA was obtained from patient A with a heterozygous
splicing-donor site mutation at exon1-intron1 (described in Section
2.2). DNA was also obtained from a control subject. PCR products were
obtained and subcloned into pcDNA3.1(+) (Invitrogen). COS7 cells
were transfected with each construct using Polyfect Transfection re-
agent (Qiagen) and incubated for 48 h. Following RNA extraction, re-
verse transcription was performed using 0.5 μg of RNA per reaction. A
primer pair speciﬁc to TPM1 5′ upstream and exon2a were used to de-
tect TPM1 products. Full procedure is available in Supplementary mate-
rial and methods.
2.5. Missense mutations of TPM1α
Full length human TPM1α cDNA was ampliﬁed using speciﬁc
primers. The TPM1α productwas cloned using the StrataClone PCR clon-
ing set (Agilent Technologies) and subcloned into pEGFP-C1 vector
(Clontech). The I130V and S229F missense mutations were introduced
to the TPM1α sequence using site-directed mutagenesis using primers
in Table S2. See Supplementary materials and methods for further
information.
2.6. Chick embryo care and maintenance
White fertile chick eggs (Gallus gallus, Dekalb White strain; Henry
Stewart) were incubated in a humidiﬁed chamber at 38 °C under con-
stant rotation [1]. Before treatment, the embryo was exposed in ovo,
and 3–5ml of albumin was removed with a syringe to separate the em-
bryo from the overlying allantoic and vitelline membranes, and both
membranes were carefully removed. After treatment, eggs were
resealed with masking tape and reincubated until harvesting. Studies
were performed within national (UK Home Ofﬁce) and institutional
ethical regulations.
2.7. Transfection of embryonic chick hearts with TPM1 missense mutant
constructs
Fertile chick eggs were incubated, as described in Section 2.6, until
HH10/11 [1], approximately 48 h. Following a published protocol [22],
a transfection mixture was prepared as follows: 4 μg of either GFP/
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fectamine in 50 μl OptiMEM, (Life Technologies), and 0.5 μl Fast Green
for visualisation. 4 μl of the transfection mixture was loaded into a
glass needle and attached to a picospritzer (Parker Hanniﬁn). Fifteen in-
jections of 3 nl transfection reagent was injected into the embryonic
pericardial space. Following incubation for a further 48 h, embryos
were extracted, placed in 4 °C PBS and checked for GFP ﬂuorescence
(SV11 stereomicroscope, Zeiss). Embryos were ﬁxed in 4% paraformal-
dehyde (PFA) for 30 min, washed with PBS and transferred to 30% su-
crose. Embryos were mounted in OCT, orientated right side facing
down and stored at−80 °C until cryosectioned at 10 μm (Leica) and
stored at−20 °C.
2.8. Immunoﬂuorescence and imaging of hearts transfectedwith TPM1mu-
tant constructs
Cryosections were processed using standard immunohistochemical
procedures (Supplementary material and methods). Images were col-
lected using a DeltaVision Elite microscope (GE Healthcare Life Sci-
ences) as Z-stacks in two separate colour channels to monitor
emission from troponin and GFP (detailed methods and parameters in
Supplementary materials and methods). Subsequent analysis of images
was performed in Fiji [23]. Representative ﬁelds of view (Fig. 3B) were
selected by choosing single Z-planes that showed clear periodic tropo-
nin sarcomeric marker.
2.9. Morpholino design
Three morpholinos were designed against TPM1 [24]: 5′
TCCCGCGAGAAGTACAGCCGAAATC3′ to translational start-site (ATG); 5′
GCTCTCAGTGCAGACCTGCTTGCTC3′ designed to the exon1-intron1
(E1I1) splice-site; 5′TTCCCTGTGTCCCAAAACTGACCTC3′ to the exon4-in-
tron4 (E4I4) splice-site (GeneTools). A standard control (SC) morpholino
was used as a positive control (5′CCTCTTACCTCAGTTACAATTTATA3′).
Morpholinos were ﬂuorescein tagged and underwent strict sequence
similarity testing ensuring gene speciﬁcity.
2.10. Application of TPM1 morpholino and embryo isolation
Morpholino application was performed as previously described [25]
using fertile chicken eggs at HH10/11 [1]. Embryos were harvested at
HH19 (81 h) using a SV11 stereomicroscope (Zeiss) to determine
morpholino uptake, stage embryos, and perform external phenotypic
analysis [26]. Data recording the numbers of chick embryos alive at har-
vesting and those that were ‘morpholino positive’ were collected and
statistically analysed (see below); n = 74 untreated (UT), 56 SC and
96 TPM1-morpholino (TPM1-MO) embryos. Embryos isolated for inter-
nal phenotypic analysis were ﬁxed in 4% PFA as previously described
[27]. See Supplementary material and methods for further information.
2.11. Systematic random sampling
Systematic random sampling [28] was used to quantify cardiac tis-
sue proportions (HH11/19). Three groups were analysed; UT (n = 6),
SC (n = 5) and TPM1-MO (n = 13) and underwent statistical analysis
(see below). A 96 point grid was placed over every third section
throughout the heart, and the tissue type on each point was identiﬁed
(12,225 points counted).
2.12. Immunoﬂuorescence and electron microscopy
Hearts processed for immunoﬂuorescence (n= 8 TPM1-MO, n = 3
control) and transmission electronmicroscopy (n=9 TPM1-MO, n=8
control) were performed as previously described [27]; see also Supple-
mentary material and methods.2.13. Proliferation and apoptosis
TPM1-MO(n=7), SC (n=3) andUT (n=3) embryoswere ﬁxed in
10% neutral buffered formalin and embedded in parafﬁn wax. Embryos
were sectioned at 5 μm using DSC1 microtome (Leica) and every 8th
section was collected on poly-L-lysine slides (Sigma). Sections were
de-parafﬁnised in xylene and rehydrated through graded alcohols. Pro-
liferationwas detected using Zymed's Proliferating Cell Nuclear Antigen
(PCNA) staining kit according to manufacturer's instructions (Zymed
Laboratories). For apoptosis detection, ApopTag®Peroxidase In Situ Ap-
optosis Detection Kit (Millipore) was used according to manufacturer's
instructions, mounted in VECTASHIELD HardSet Mounting Media with
DAPI (Vector laboratories) and imaged using the Axioskop 2 (Zeiss)
and Openlab (PerkinElmer). Total cell number (DAPI plus DAB reactive
cells) was used in order to calculate the ratio and proportions of prolif-
erating/apoptotic cells for each heart.
2.14. Isolation of cell micromass from embryonic chick hearts, morpholino
treatment and analysis
Cardiac cells were isolated from day 5 embryonic chicks using previ-
ously described methods [29]. After 24 h, 10 mM of TPM1-MO was
added to the cardiac cell micromass and cells were incubated for 48 h.
Cells were ﬁxed in 4% PFA and immunostained with anti-troponin T an-
tibody (DSHB). Cells were visualized using the DMIRE2 inverted micro-
scope (Leica). Cardiomyocytes treated with TPM1-MO were classiﬁed
into four stages depending on the degree of sarcomeric maturity (Fig.
7A). Stage one consisted of cells with positive staining around the pe-
riphery of the cell but no sarcomeric structures can be clearly seen, es-
pecially around the nucleus (Fig. 7Aa). Stage two cardiomyocytes
contain assembled sarcomeres; however, they appear thin and
disorganised (Fig. 7Ac). Stage three cardiomyocytes present with
organised sarcomeres that appear thin but are organised and run paral-
lel to one-another (Fig. 7Ae). Finally, stage four cardiomyocytes contain
mature sarcomeres with thick bands running through the cell (Fig.
7Ag). See Supplementary material and methods for detailed protocol.
2.15. Electrical activity
Intracellular recordings from TPM1-MO embryos (HH11/19; n = 3)
and control (n=3) spontaneous beating heartswere performed as pre-
viously described [27,30]. See Supplementary material andmethods for
details.
2.16. Statistics
Levene's test for equality of variances was used followed by a t-test
for equality of means using SPSS V21.0 (SPSS); P b 0.05 was considered
as signiﬁcant. Where appropriate, the mean ± SEM was calculated.
3. Results
3.1. Mutations in TPM1 are associated with CHDs
To determine whether CHD patients carry TPM1mutations, 380 pa-
tients with a range of heart phenotypes were screened. Four variants
were identiﬁed: one splice-donor site mutation, a polyadenylation sig-
nal variant and two non-synonymous missense mutations. The splice-
site mutation was identiﬁed in patient A with tetralogy of Fallot (TOF;
characterized by outlet ventricular septal defect with anterocephalad
deviation of the outlet septum resulting in the aortic valve over-riding
the interventricular septum, pulmonary stenosis and right ventricular
hypertrophy). This mutation occurred in the donor-site of intron1/2,
and consisted of a thymine to cytosine transition in the second nucleo-
tide of the consensus (IVS1 + 2T N C; Fig. 1A). Patient B had pulmonary
atresia (malformed pulmonary valve) and an intact interventricular
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tal defect and persistent ductus arteriosus [elements of the fetal circula-
tion required for postnatal survival to permit treatment; a
communication remaining between the aortic arch and pulmonary
trunk]). At the time of diagnosis, an A N G transition was detected (Fig.
1B). The mutant allele encodes a TPM1 protein where an isoleucine is
replaced by a valine residue at position 130 (I130V). A C N T transition,
encoding a mutant S229F protein, was found in patient C with an ASD
(Fig. 1C). These three mutations mentioned above are not present on
any public databases. For all three cases we were not able to assess
the de novo status of the variants as we do not have access to one or
both parental samples.
The polyadenylation signal variant replaces adenine for guanine in
the ﬁrst position of the consensus (GATAAA/AATAAA). It was discov-
ered in patient D with two ASDs and secondary dilation of the right
heart chambers (Fig. 1D). It is likely that the right heart dilatation is sec-
ondary to the left to right atrial shunt, although a right heart myocardial
abnormality in association with atrial septal communications can also
be the primary lesion on rare occasions. This polyadenylation variant
has been seen in three individuals with no abnormal heart phenotype
in the population (n = 2504, phase 3 of 1000 genomes project; SNP
rs545752658). Because of its presence in non-affected individuals, at
present it is difﬁcult to support a substantial causal role for this variant.
All four variants were absent in the ethnically matched control sample
cohort (n = 384, UK blood donors, Sigma-Aldrich) and no additional
coding variations of TPM1 were observed in the control cohort.
3.2. Investigating the effect of a novel splice-donor site mutation in vitro
To assess the functional consequence of a novel TPM1 splice sitemu-
tation, two constructs were created, spanning the 5′ upstream region of
TPM1 to exon 2a, using patient A and a control's genomic DNA (Fig. 1E).
Constructs contained either the IVS1 + 2T N C splice site mutation, or
wild-type TPM1. RT-PCR showed that the wild-type produced a tran-
scribed TPM1 product of 307 bp whilst no concurrent product was
seen for the splice-site mutation construct (n = 3; Fig. 1F).
3.3. In silico analysis of missense mutations I130V and S229F in TPM1
The I130V mutation results when an adenine in exon 4, which is
highly conserved, is replaced with guanine. Both isoleucine and valine
are non-polar at physiological pH. However, the amino acid substitution
is located in the d position of the seven residue heptad repeats. Addi-
tionally, the mutation is located within the fourth α-zone of TPM1.
The S229F mutation occupies a conserved position through evolu-
tion, as shown in Fig. 2A, where serine or threonine exist in birds, ﬁsh,
mammals, X. tropicalis, Drosophila and C. intestinalis. Both residues
have small, polar side chains. S229F mutant allele encodes a protein in
which a phenylalanine residue occupies this position. A molecular ho-
mology model of the S229F TPM1 predicts that the much bulkier, non-
polar side chain of phenylalanine would impair binding of two TPM1
peptide molecules that form the coiled-coil tropomyosin ﬁlament by
steric hindrance (Fig. 2B–D).
3.4. Analysis of I130V and S229Fmissensemutations in the embryonic chick
heart
To investigate the functional consequences of the missense muta-
tions, chick HH11 hearts were transfected and subsequently harvestedFig. 1. Sequence traces demonstrating TPM1mutations in patients with CHDs and the effect o
corresponding to the CHD samples with a TPM1 gene mutation. The right panel shows the nu
observed. E. Schematic illustration of TPM1. Two variants were found in intron1-2a: IVS1 + 2
variants from the genomic DNA of patient A (PR1 in the 5′ upstream region and PR2 in exon
the 1st open reading frame. ATG, ATG start-site; E, exon; UTR, untranslated region. F. PCR sho
wild-type mRNA splices normally, giving an expected band size of 307 bp (+lane), the IVS1
The –ve RT (−lane) and PCR controls (H20) showed no signal.atHH22; the GFP-tagged constructswere found to transfect successfully
(Fig. 3A). Hearts transfected with either GFP/TPM1-WT, GFP/TPM1-
I130V or GFP/TPM1-S229F constructs (n= 4 per group) were analysed
with immunoﬂuorescence for the sarcomeric structural protein, and Z-
stack imaging of sectioned hearts was performed. Examination of single
z-planes showed that cardiomyocytes successfully transfected; GFP/
TPM1-WT had coincident localisation of the sarcomeric marker
troponin T and GFP (n = 15 sarcomeres; the arrow landmarks in
Fig. 3Ba, a′ compared to Bb, b′ and merged image Bc, c′; regions of
peak troponin T and GFP signal show white, i.e. magenta plus green).
The coincident punctate expression was further demonstrated by plot-
ting the ﬂuorescence intensity along sarcomeric sections (Fig. 3Bd).
Transfecting cardiomyocytes with GFP/TPM1-I130V led to GFP
expressed in a punctate pattern but the troponin marker did not coin-
cide (n=13; see the positionsmarkedwith arrows in Fig. 3Be, e′ show-
ing the absence of troponin Tmarker to those in Bf, f′ showing punctate
GFP at the same location, and in the merged image Bg, g′). This was
again conﬁrmed with ﬂuorescence intensity plots (Fig. 3Bh); note that
the (low intensity) peaks observed in the troponin channel (Fig. 3Bh)
originate from z-planes above or below the one shown, i.e. out-of-
focus objects that are not apparent in the single-z-plane images. In ad-
dition, one sarcomere observed expressed the troponinmarker in an al-
ternating fashion to the GFP expressing TPM1-I130V construct. GFP/
TPM1-S229F transfected cardiomyocytes appeared similar to the GFP/
TPM1-I130V expressing sarcomeres, where troponinwas not expressed
in the same region for themajority of the sarcomeres analysed (n= 16;
arrowed locations Fig 3Bi, j and k) and conﬁrmed byﬂuorescence inten-
sity plot (Fig. 3Bl). Further, as seen for TPM1-I130V, one GFP/TPM1-
S229F sarcomere showed alternating expression of GFP and troponin
(n = 1; Supplementary Fig. 1).
3.5. Looping defects seen upon TPM1 morpholino treatment
To assess TPM1 requirement during heart development, embryos
were morpholino-treated at HH10/11 and harvested at HH19. Survival
rates for the untreated (UT; n = 81), standard control (SC; n = 92)
and TPM1-morpholino treated groups (TPM1-MO; n = 123) were
91.4%, 89.1% and 88.6%, respectively (P=0.98). Following ‘morpholino
uptake’ determination in surviving embryos, 68.3% SC and 88.1% TPM1-
MO treated embryos were positive (P= 0.76).
Embryos were externally analysed upon harvesting. The UT and SC
groups all appeared phenotypically normal, hence the groups were
pooled (n = 137; Table 1; Fig. 4A, B). Following application of TPM1-
MO, the external phenotype of embryonic hearts appeared normal for
the majority of embryos (Fig. 4C; 92/96, 96%). In the 4% that appeared
abnormal (4/96), the hearts were dextrally distorted, indicating a
looping defect (Table 1; Fig. 4D, E). Stereological analysis showed no
proportional differences of cardiac atrium, ventricle or OFT between
the control and TPM1-MO groups (P= 0.3; Fig. 4F).
3.6. TPM1 is required for normal atrial septa and trabeculae formation
Embryos were transversely, serially sectioned to analyse internal
structures. The septum appeared to develop normally (extending from
the atrial wall roof towards the AV canal) in all controls (n = 60;
Table 1; Fig. 5Aa, b, d, e). In 41% of the morpholino-treated embryos,
the septum was small and resembled a knuckle shaped outgrowth
from the atrial myocardium (n = 28/69; Table 1; Fig. 5Ac, f). One
heart displayed a remarkable septal phenotype with the initiation of af a splice-donor site mutation on splicing. A, B, C, D. dHPLC traces and electropherograms
cleotide substitution for each variant. Arrows demarcate variation in the DNA sequence
T N C (indicated as T N C). Primers were designed to obtain amplicons containing these
2a). Five stop codons are present within intron 1-2a (S72, S204, S348, S357 and S366) in
wing the splicing of TPM1 containing IVS1 + 2T N C mutation versus the wild-type. The
+ 2T N C mutant produce no splice product. β-actin acted as a loading control (249 bp).
Fig. 2.Multi-species amino acid alignment of a TPM1 segment and molecular modelling of TPM1 demonstrating alterations at residue 229. A. Multi-species alignment of orthologues of
TPM1 showing the conservation of residue 229 (red rectangle). In this position, serine or threonine are present in mammals, ﬁsh, amphibians, insects and ascidians. B–D. Homology
molecular models showing the structure of the residues serine (B), threonine (C) and phenylalanine (D) in position 229 of TPM1. Serine or threonine, which are conserved, allow
proper interaction between two TPM1 molecules forming coiled-coil dimers whereas, phenylalanine with its bulkier side chain, encoded by the S229F allele, prevents that interaction,
by steric clash between the two molecules.
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quential tissue analysis revealed the appearance of the septum proper
(Fig. 5Ba), adjacent to a second septum (Fig. 5Bb). These septa
progressed in size, with the septum proper achieving close to normal
septal length (Fig. 5Bc, d). Finally, when approaching the posterior
atrial wall, the septa fused to form one common septum (Fig. 5Be, f).
Stereological data showed that the atrial septum represented 0.61 ±
0.13% in the control hearts (n = 11) and 0.42 ± 0.11% in the TPM1-
MO hearts (n = 13), a 30.18% decrease in atrial septation compared to
control groups.
Trabeculae appeared normal in control groups (n= 60; Table 1; Fig.
5Ca, b). In TPM1-MOhearts, 38% had abnormal trabecular development,
with a severe reduction in number and size (n = 26/69; Table 1; Fig.
5Cc). One heart completely lacked deﬁned trabeculae (Fig. 5Cd). Stereo-
logical analysis showed the ventricular wall and trabeculae in control
hearts represented 16.18 ± 0.87% of the hearts proportion, while the
TPM1-MO ventricular wall and trabeculae accounted for 12.68 ±
0.60%; a decrease of 21.64% (P = 0.003; Fig. 5D). Consistent with this,
the ventricular lumen for the control and TPM1-MO hearts accounted
for 20.17 ± 2.72% and 28.90 ± 2.37% respectively, an increase of
43.25% in TPM1-MO groups (P=0.024; Fig. 5D). Embryos that present-
ed with the abnormal looping phenotype all presented with abnormal
atrial septa or reduced trabeculae.
From all the embryos assessed in this study, 55% (38/69) had either
an abnormal septum or reduced trabeculae, while 23% (16/69) present-
ed with both of the abnormal phenotypes.
3.7. TPM1 morpholino treatment results in cell death
Apoptosis was quantiﬁed in TPM1-MO hearts from a total of
28,103 cells. No differences in apoptosis were observed between
UT and SC hearts, and were pooled into one control group (n = 3
for both UT and SC; P N 0.087). In the atrial wall, 0.47 ± 0.07% of
the control and 0.95 ± 0.24% of the TPM1-MO heart cells were apo-
ptotic (n = 7 TPM1-MO hearts; P N 0.05; Fig. 6). In the atrial septum,
apoptosis accounted for 0.49 ± 0.06% cells in control and 1.56 ±0.27% in TPM1-MO treated hearts (P b 0.001; Fig. 6). Finally in the
ventricular wall, 0.43 ± 0.05% of the cells were apoptotic in control
hearts compared to 0.68 ± 0.05% in TPM1-MO hearts (P = 0.013;
Fig. 6).
Cell proliferation was analysed in the same hearts from a total of
47,747 cells. No signiﬁcant differences in PCNA positive cells were
seen between the SC and UT hearts (P N 0.085) and were pooled. Cell
proliferation appeared normal in the atrial wall, atrial septum and
ventricular wall in the TPM1-MO hearts when compared with controls
(P N 0.271).
3.8. TPM1 morpholino treatment reduces sarcomeric maturity
The effect of TPM1-MO on sarcomere assembly was investigated
using cardiac cell micromass. Control and TPM1 treated cardiomyocytes
were classiﬁed into four stages depending on the degree of sarcomeric
maturity (see Section 2.14; Fig. 7A). Stage one consisted of cells with
positive staining around the periphery of the cell with identiﬁable sar-
comeric structures not seen (Fig. 7Aa, b). Stage two cardiomyocytes
had thin and disorganised sarcomeres (Fig. 7Ac, d). Stage three
cardiomyocytes had thin, organised sarcomeres that run parallel to
one-another (Fig. 7Ae, f). Finally, stage four cardiomyocytes containma-
ture, thick sarcomeres (Fig. 7Ag, h).
UT and SC cells showed no difference in any of the classiﬁcations and
were pooled into one control group (n=753 cells; P N 0.217).When the
control group was compared with the TPM1-MO group (n = 273),
the TPM1-MO cells had signiﬁcantly more sarcomeres at stage 1 and 2
(P b 0.001 and P = 0.012, respectively; Fig. 7B). No difference was
seen at stage 3 between the groups (P= 0.120), however, the number
of TPM1-MO cells with stage 4 sarcomere assemblywas signiﬁcantly re-
duced (P b 0.001).
Following tissue integrity investigations, no differences between
TPM1-MO (Supplementary Fig. S2; n = 8 TPM1) and control (Fig.
S2A; n = 3) hearts were observed when using sarcomeric (alpha-
actinin; red label in top panels Fig. S2A&B) or plasma membrane
(beta-catenin; green label in top panels Fig. S2A&B) markers. At the
Fig. 3.Whole embryonic hearts transfected with GFP-tagged constructs and visualized on a DeltaVision microscope. A. Embryo microinjected with GFP-tagged constructs and harvested
48 h post-injection (n= 4 per group). GFP ﬂuorescence was restricted to the heart. B. Photomicrographs of sarcomeres transfected with control (a–c), GFP/TPM1-I130V (e–g) and GFP/
TPM1-S229F (i–k) constructs. The sarcomeres showing GFP expression (green; panels b, f, j) can be compared to the same region (arrows landmark the same positions) counter stained
with the TRITC labelled troponin sarcomeric marker (magenta; panels a, e, i); merged images presented in c, g and k (magenta and greenmerge showswhite). Boxed areas denote higher
magniﬁcations (a′–k′). Wild-type show coincidence of the GFP and the troponin marker (arrows in a′, b′ and c′; white shows overlap of similar green and magenta signals). This is
supported by the ﬂuorescence intensity plot (d) (obtained from region denoted with a line in c), with peaks for GFP and TRITC correlating. In contrast, with the I130V mutant,
coincidence of the GFP construct was not observed with the troponin sarcomeric marker (e′, f′ and g′; i.e. the sarcomere is not evident at the arrows in e′ but is at the same location
(arrows) in f′); in the intensity plot (h) correlation of TRITC did not occur with GFP (region denoted with dotted line in g). This was also true for the S229F mutant, where coincidence
of GFP was not seen with troponin (i′, j′ and k′; supported by the intensity plot in l with region denoted with dotted line in k). Note that the low intensity peaks (see the scale for
TRITC ﬂuorescence in h with that in d) observed in the troponin channel in h come from ﬂuorescence from adjacent z-planes, i.e. out-of-focus objects not apparent in the image.
Similarly, the TRITC peak in l comes from a ‘crossing’ sarcomere. Images shown are representative of sarcomeric phenotypes for each experimental group. Scale bar in c, g and k is 10
μm, and in c′, g′ and k′ is 2 μm.
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guishable from each other when cellular structures such as myoﬁbril
assembly, presence of desmosomes and mitochondria, were analysed
(n = 9; Fig. S2C).3.9. TPM1-MO hearts displayed altered action potentials
Intracellular recordings were obtained from single spontaneous
beating cardiomyocytes from the atria and ventricles of TPM1-MO
Table 1
Summary of phenotypic analysis following treatment with TPM1 morpholinos.
Stagea Embryo typeb
Heart shape Atrial septum Trabeculation
Totalc
int
Ab looping Normal Totalc
ext
Double Reduced Normal Absent Reduced Normal
HH11/19 Control – 137 137 – – 60 – – 60 60
TPM1
ATG
2 34 36 1 11 17 1 12 16 29
TPM1
E1I1
1 28 29 – 9 17 – 5 21 26
TPM1
E4I4
1 30 31 – 7 7 – 8 6 14
Assessment of heart shape based on qualitative analysis of gross morphological features.
Qualitative assessment of septation and trabeculation obtained from serial histological sections.
Ab, abnormal; ext, externally; int, internally.
a Stage of development when morpholino treatment/harvesting performed.
b Control embryos include standard control and untreated; TPM1 denotes embryos treated with tropomyosin 1 ATG or splice site morpholino.
c Total number of embryos analysed.
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ventricular) hearts. APs from TPM1-MO ventricular cardiomyocytes
had signiﬁcantly decreased amplitudes, with atrial cell amplitudes
comparable to controls (Fig. 8A; representative traces for atrial
cells Fig. 8C and ventricular cells Fig. 8D). In contrast, both atrial
and ventricular cells from TPM1-MO hearts exhibited shorter AP du-
rations (Fig. 8B; representative traces in Fig. 8C&D respectively) and
increased maximal δv/δt compared to controls (Fig. 8E; representa-
tive traces Fig. 8F&G). APs were altered in 100% of TPM1-MO cells
analysed.
4. Discussion
TPM1 is a parallel double-stranded α-helical coiled-coil protein,
which binds to the long grooves of actin, making it crucial in actin reg-
ulation and stability [31]. It also functions with the troponin complex
in response to Ca2+ [17]. Two isoforms of the TPM1 gene, TPM1α and
TPM1κ, are expressed in equivalent amounts in both the fetal and
adult human heart and differ by the inclusion of either exon 2b or
exon 2a, respectively. At the protein level, however, TPM1α accounts
for about 92% of total TPM protein, with TPM1κ and TPM2α (protein
product from the TPM2 gene) making up the remainder [32,33]. TPM1
has recently been associated with CHDs in a two year old female with
Ebstein anomaly, left ventricular non-compaction, pulmonary hyper-
tension and end-stage heart failure [14]. The de novo mutation wasFig. 4. TPM1-morpholino treatment leads to abnormal looping. Embryos were treated at HH11
External phenotypic analysis shows a subset of TPM1-MO embryos displayed looping defects (
137 and 96, respectively; A–C). Stereological analysis revealed normal cardiac tissue proportio
and 13, respectively; F). Scale bars: 500 μm. h, head; asterisk, outﬂow tract; OFT, outﬂow tractfound in a highly conserved region of exon 4, D159N, and an actin bind-
ing region of TPM1.However, thismutationwas not associatedwith iso-
lated CHD's, unlike the mutations reported in the current study.
To determine a role for TPM1 in human cardiogenesis, 380 individ-
uals with isolated CHD's were screened. Given that we and others
have shown that Mendelian CHD often shows variable expressivity
[15,34] including malformations without obvious causal or taxonomic
relation even in the presence of an identical mutation, we decided to in-
clude patients with any type of CHD. Four novel mutationswere detect-
ed; twomissense, a splice site and a polyadenylation signal variant. T N C
substitutions in the splicing donor-site are known to cause human dis-
ease when present in other genes [35,36]. The most likely outcome of
thesemutations is intron1/2 inclusion inmaturemRNA, the use of cryp-
tic donor sites in the same intron or in the adjacent exon, or exon skip-
ping [37,38]. In this study the splice site mutation IVS1 + 2T N C, found
in patient Awith TOF,was analysed in vitro; it did not result in the use of
cryptic donor sites (ﬁrst one located 137 bases downstream of the
donor-splice site), since no RT-PCR product was produced (Fig. 1F).
Therefore, the donor-splice site in the ﬁrst intron of TPM1 is essential
for the production of normal RNA products.
The I130Vmutation is locatedwithin the d position of the heptad re-
peat of TPM1, the region responsible for giving TPMs their coiled-coil
property [39]. In addition, the I130V mutation is located within the
fourthα-zone of the TPM1protein,which has been proposed to interact
with subdomains 1 and3 of F-actin, in the context of the sarcomere [31].and harvested at HH19 (HH11/19) for both the control (A, B) and TPM1-MO (C–E) groups.
n= 4; D, E) in comparison to control and normally looped TPM1-MO embryo hearts (n=
ns (atrium, ventricle and outﬂow tract) between control and TPM1-MO embryos (n= 11
; v, ventricle.
Fig. 5. TPM1morpholino treatment results in abnormal atrial septa and trabeculae formation. A. Untreated (UT), standard control (SC) (a, b, d, e), and TPM1-MO (c, f) hearts were imaged
at low (top panel) and high (lower panel)magniﬁcations. The septum in the TPM1-MOheart (c; n=27/69)was smaller compared to control hearts (a, b; n=60). Scale bars a–c: 100 μm;
d–f: 200 μm. B. Serial sections through one TPM1-MO embryo revealed a double septum. One septum originated from the atrial wall (a), followed by a second, smaller septum (b, c, d).
Deeper sections showed the fusion of these two septa (e, f). Scale bar: 200 μm. Arrows denote septa. C. UT and SC embryos contained normal trabeculae projecting into the ventricular
chamber (a, b; n = 60). In contrast, TPM1-MO hearts showed reduced trabecular size and number (c; n = 25/69) or complete absence of trabeculae (d; n = 1/69). Asterisks denote
trabeculae. Scale bar: 100 μm. D. Stereological analysis of heart regions revealed that TPM1-MO hearts had decreased ventricular wall and trabeculae proportions (denoted as Vent
wall) and an increased ventricular lumen size compared with controls. Mean± SEM; *P b 0.05. Asterisk, trabeculae; At, atrium; ECM, extracellular matrix, OFT, outﬂow tract; V, ventricle.
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may affect the stability of the coiled-coil structure of TPM1 [40]. Howev-
er, the side-chain of the valine residue encoded by the derived allele is
smaller than that of the isoleucine encoded by the ancestral allele, and
both are predicted to adopt the same orientation, i. e. towards the oppo-
site TPM1 molecule of the dimer, so they would form part of theinterface surface between them. Thus, it is unlikely that this mutation
compromises the stability of the coiled-coil by steric hindrance. Never-
theless, the space left by a smaller valine side-chain could alter dynam-
ics of the coiled-coil dimer through the contractile cycle, but, in order to
support this notion further, a dynamic structural model of the TPM1
dimer would be required, which is not currently available. The S229F
Fig. 6. Apoptosis increased in the atrial septum and ventricular wall of TPM1-MO hearts.
Apoptosis was measured in UT, SC (pooled as controls; n = 6) and TPM1-MO hearts
(n = 7). Apoptosis was signiﬁcantly increased in the atrial septum and ventricles of
TPM1-MO hearts, *P b 0.05 ***P b 0.001.
Fig. 7. TPM1-MO treatment leads to immature sarcomere assembly. A. Sarcomere assembly wa
cell with no ﬁbril structures present (Aa and b); stage 2 ﬁbres present in a disorganised fashion
running across the cell (Ag and h). Control indicates cells that were not treatedwith TPM1morp
B. TPM1-MO treatment resulted in signiﬁcant increases in stage 1 and stage 2 immature cells
number of stage 3 cells. *P b 0.05 ***P b 0.001.
10 J. England et al. / Journal of Molecular and Cellular Cardiology 106 (2017) 1–13mutation occupies a conserved position through evolution, where ei-
ther the small, polar residues serine or threonine exist (Fig. 6A). The
S229Fmutant allele encodes a protein inwhich a phenylalanine residue
occupies this position. As shown in Fig. 2B–D, the S229F substitution is
predicted to impair binding of TPM1 peptides since phenylalanine is
non polar and much bulkier than a serine residue. Both of these novel
missense mutations, therefore, may affect the stability of the TPM1
structure and stability within the sarcomere. As mentioned in Section
3.1, we were unable to assess the de novo status of the I130V, S229F
and splicing site variants, as we lack critical parental samples. Neverthe-
less, we [5,15] and others [34,41] have shown that mutations causing
MendelianCHDoften show incomplete penetrance and variable expres-
sivity which means that, even in the case of a variant present in an un-
affected parent, this could be pathogenic.
In ovo transfection using TPM1 constructs containing the novel mis-
sense mutations, I130V and S229F, revealed the absence of co-
localisation between the two thin ﬁlament proteins, troponin T and
the GFP/TPM1 mutant construct (Fig. 3Be–g, i–k). However, in the
GFP/TPM1-WT sarcomeres, both proteins were always co-localised
(Fig. 3Ba–c); therefore, the phenotypes seenwere speciﬁc to themutants categorized into 4 stages: stage 1 immature myoﬁbril assembling at the periphery of the
(Ac and d); stage 3 thin but organised ﬁbrils (Ae and f); stage 4 fully developed thick ﬁbrils
holino, while TPM1-MO indicates cells treatedwithmorpholino for 48 h. Scale bar: 16 μm.
, signiﬁcant decreases in the number of stage 4 cells and reduced (but not signiﬁcantly)
Fig. 8. TPM1-MO treatment alters action potentials in cardiomyocytes. A–D. Graphs showing changes in AP amplitude (A) and duration (B) between atrial and ventricular cardiomyocytes
in control and TPM1-MO hearts. Representative AP traces from atrial (C) and ventricular cardiomyocytes (D) for control (black traces) and TMP1-treated (dotted traces) hearts were
superimposed to show amplitude and duration changes. E–G. Graphs showing changes in the rate of depolarisation (δv/δt) of the atrial and ventricular cardiomyocytes from control
and TPM1-MO hearts (E). Representative AP traces of the maximal δv/δt from both atrial (F) and ventricular (G) cardiomyocytes for control (black traces) and TPM1-MO hearts
(dotted traces) are shown.
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studies investigating the central region of TPM1 (residues 145–235)
have shown its interaction with the troponin complex is intrinsically
unstable [42,43]. Alterations within the TPM1 central region are be-
lieved to affect Ca2+-mediated activation of the thin ﬁlament, because
of its interaction with the troponin complex. This in turn would affect
the terminal ends of TPM1 (where TPM1 binds to the next TPM1mole-
cule) and affect its contractile function [44,45]. Substitution of a nega-
tively charged glutamic acid at position 229 of TPM1 (S229E)
increased the distance between the helical interwinding of TPM1mole-
cules and affected cardiac contractility [46]. Therefore, subtle changes in
TPM1 conformation can have dramatic effects within the sarcomere.
We propose that these novel missense mutations result in alterations
to the coiled-coil structure of TPM1 and may affect its incorporation
into the thin ﬁlament and/or its association with other thin ﬁlament
proteins [47].
The alternating expression of troponin T with GFP/TPM1-I130V and
S229F observed in one sarcomere may be explained by the close associ-
ation of two adjacent sarcomeres winding or twisting around each
other. This is consistent with the absence of this alternating expression
in wild-type sarcomeres, which showed only GFP and troponin marker
co-expression.
The variant detected in the 3′ untranslated region in patient D with
two ASDs and dilated right chambers modiﬁes the ﬁrst base of the se-
quence of the polyadenylation signal (AATAAA/GATAAA). Mutations
of the polyadenylation signal can cause human disease [48], and
speciﬁcally, has been shown that this particular substitution
reduces the efﬁciency of the cleavage of the mRNA precursor at the
polyadenylation site to approximately 30% of the wild-type sequence
whereas the polyadenylation itself is reduced to 11% [49]. However,
the effect of these mutations could be potentially ameliorated by the
use of alternative downstream polyadenylation signals. Interestingly,
the polyadenylation signal variant seen in our study is also locatedwith-
in an experimentally validated binding-site for microRNA-21 which
downregulates TPM1 expression [50]. MircroRNA-21 plays a role in car-
diac disease, and impairment of its function resulted in regression of
cardiac hypertrophy and ﬁbrosis in a mouse model of left ventricular
overload [51]. Nevertheless, the variant occurs in the 3´UTR segment
that binds the 3′ end of miR-21, and typically, mismatches in such re-
gions do not modify strongly the afﬁnity of microRNAs. Given that this
variant has also been found in unaffected subjects, this suggests a
weak correlation with the presence of cardiac malformation. Therefore,
with the evidence available, the pathogenic potential of the variant de-
tected in the 3′ untranslated region is uncertain.From ours and previous studies, we can hypothesize that mutations
in genes for proteins of the thick (i.e.MYH6) [15] and thin ﬁlaments (i.e.
ACTC1 [7] and TMP1, the present report) of the sarcomere expressed in
the human developing heart can cause cardiac malformation,
supporting the notion that early intra-cardiac blood ﬂow has evolved
as an important epigenetic factor contributing to adequate
cardiogenesis [52].
Many isoforms of TPM1 exist through alternate splicing. Two striated
isoforms are known to be expressed in the developing chick heart,
TPM1α and TPM1κ, as well as smooth muscle and ﬁbroblast isoforms
(expression proﬁles were conducted on a 4-chambered and relatively
mature heart at day 10 and 15 of embryonic development) [53]. This ex-
pression suggests roles for this actin-binding protein in the contractile
system of both striated and smooth muscles cells, and in the cytoskele-
ton of non-muscle cells were it has a stabilising function. Targeted ma-
nipulation of TPM1 was performed early in chick cardiogenesis, at
HH10/11 or 2 days post-fertilisation, to gain insight to the role of
TPM1 during early heart development. Three different morpholinos
were used to target different regions, and the resulting phenotypes
remained consistent between these morpholinos. Morpholinos have
come under criticism recently, due to off-target effects in zebraﬁsh
[54]. Thus we conclude that we did not observe off-target effects in
this study. However, in order to study the role of TPM1 in speciﬁc line-
ages during development, cardiac-speciﬁc knockout of TPM1 in these
lineages will need to be performed in the mouse, with such speciﬁc
markers not yet available.
Although a Tpm1−/− mouse has been created, embryos died be-
tween E8.5–11.5 and were only recently characterized [55,56]. These
homozygousmice had thin ventricularwallswith fewer, thinner trabec-
ulae, enlarged intracellular spaces and extended cellular processes with
smaller adherens junctions and myoﬁbrils failed to form [56]. Since the
Tpm1−/− mouse dies early in development, and phenotypic analysis
was conducted as the embryos were already undergoing resorption
[56], it calls to question whether or not the observed phenotypes were
down to the absence of Tpm1, or because the embryos were fated.
Therefore, morpholinos can be a useful tool if carefully controlled, as
they can be used later and at precise stages.
Although no individual phenotype had 100% penetrance, 58% of
TPM1-MO embryos analysed internally showed abnormal pheno-
type(s). Of those analysed externally, 4% of embryos had an abnormal
phenotype and also had reduced trabeculae and/or abnormal atrial
septation. Stereological analysis revealed an underdeveloped ventricle,
with reduced ventricular wall and trabeculae, and increased ventricular
lumen size in TPM1-MO embryos. In addition, stereological analysis
12 J. England et al. / Journal of Molecular and Cellular Cardiology 106 (2017) 1–13indicated that the atrial septum was also reduced in size, although this
could not be statistically conﬁrmed since the septum is small and did
not reach the optimal number of grid points (63 out of a required 200
points were counted) [28]. These phenotypes may be explained by the
statistically increased apoptosis in these regions (Fig. 6).
TPM1-MO treatment resulted in increased immature myoﬁbrils. In
the Tpm1−/− mouse, myoﬁbril assembly was ablated and thick and
thin ﬁlaments failed to interact [56]. Similarly, the cardiacmutant axo-
lotl heart had reduced Tpm1, resulting in failure of myoﬁbrils to assem-
ble [57,58]. In this study, sarcomere assembly was initiated but
myoﬁbrils remained nascent; however morpholino treatment was per-
formed after the initial heart tube had formed and therefore, TPM1was
already present in the heart. Conversely, in the Tpm1−/−mouse and car-
diacmutant axolotl, Tpm1 is absent or diminished from the offset there-
fore leading to a more severe phenotype.
Intracellular recordings from atrial and ventricular cells treatedwith
TPM1-MO revealed altered APs. Interestingly, 100% of the recorded cells
had affected APs, while only 58% of the TPM1-MO treated hearts
displayed morphological abnormalities. This may indicate that the con-
tractilemachinery of the cellsmay bemore sensitive to TPM1-MO treat-
ment and the structural phenotype may be a secondary defect; the
abnormal contraction leads to changes in haemodynamics and hence
to developmental defects [59,60]. The increased δv/δt indicates an in-
crease in active Na2+ channels during depolarisation of the AP, while
the decrease in amplitude and duration suggests a decrease in L-type
ICa2+ channels and an increased number of active IK+ channels [61]. In em-
bryonic myosin heavy chain (eMHC) morpholino treated hearts, APs
were also affected with decreased amplitudes and increased durations
and δv/δt [27]. There was a dramatic change in Ca2+ transients which
prolonged the duration of the AP. Therefore, investigating the transients
of ions within TPM1-MO treated hearts may elucidate the cause of the
abnormal APs.
Previous studies reported that alterations in cardiac conductivity
have a morphological effect on cardiogenesis. Connexins (gap junction
proteins) ensure the propagation AP throughout cardiac muscle [62].
In the Connexin40 deﬁcient and null mouse, electrical conduction is re-
markably impaired [63] and animals displayed VSD (opening between
ventricular chambers), double-outlet right ventricle, TOF, endocardial
cushion defects, biﬁd atrial appendage and aortic arch defects at an inci-
dence of 18% and33%, respectively [64]. Obvious changes in the contrac-
tion patterns of TPM1-MOhearts were not observed, although on-going
experiments using atomic force microscopy may assist in evaluating
such possibilities.5. Conclusion
To date, a range of genes have been associated with isolated CHDs,
from transcription factors, ligands and their receptors to structural pro-
teins [65,66], withmutations in these structural proteins also associated
with cardiomyopathies [67,68]. It is of note that some mutations in
these genes have been associated with a wide spectrum of CHDs,
which may occur as a single defect or in combination, such as ASDs,
transposition of the great arteries, TOF and VSD [5–7,15]. This study
demonstrates that TPM1 plays a crucial role in cardiogenesis, both struc-
turally and physiologically. Functional analysis of novel human muta-
tions has provided proof that TPM1 is a candidate gene worthy of
further screening for cardiovascular disorders.Funding
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